Affimed Return on Investment 2014-2024 | AFMDQ
Current and historical return on investment (ROI) values for Affimed (AFMDQ) over the last 10 years.
| Affimed ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2024-09-30 |
$-0.08B |
$0.02B |
-173.71% |
| 2024-06-30 |
$-0.09B |
$0.04B |
-141.46% |
| 2024-03-31 |
$-0.10B |
$0.05B |
-124.01% |
| 2023-12-31 |
$-0.12B |
$0.07B |
-108.49% |
| 2023-09-30 |
$-0.12B |
$0.09B |
-93.94% |
| 2023-06-30 |
$-0.12B |
$0.12B |
-73.42% |
| 2023-03-31 |
$-0.11B |
$0.15B |
-58.31% |
| 2022-12-31 |
$-0.09B |
$0.17B |
-49.86% |
| 2022-09-30 |
$-0.09B |
$0.20B |
-47.72% |
| 2022-06-30 |
$-0.09B |
$0.22B |
-51.11% |
| 2022-03-31 |
$-0.09B |
$0.15B |
-51.87% |
| 2021-12-31 |
$-0.08B |
$0.18B |
-39.95% |
| 2021-09-30 |
$-0.06B |
$0.17B |
-36.80% |
| 2021-06-30 |
$-0.04B |
$0.19B |
-30.66% |
| 2021-03-31 |
$-0.03B |
$0.22B |
-33.08% |
| 2020-12-31 |
$-0.04B |
$0.08B |
-71.56% |
| 2020-09-30 |
$-0.04B |
$0.06B |
-87.15% |
| 2020-06-30 |
$-0.05B |
$0.05B |
-134.23% |
| 2020-03-31 |
$-0.05B |
$0.04B |
-139.01% |
| 2019-12-31 |
$-0.04B |
$0.04B |
-94.87% |
| 2019-09-30 |
$-0.01B |
$0.03B |
-29.81% |
| 2019-06-30 |
$-0.01B |
$0.04B |
-26.67% |
| 2019-03-31 |
$-0.01B |
$0.05B |
-23.65% |
| 2018-12-31 |
$-0.02B |
$0.05B |
-41.07% |
| 2018-09-30 |
$-0.04B |
$0.04B |
-78.14% |
| 2018-06-30 |
$-0.04B |
$0.06B |
-68.52% |
| 2018-03-31 |
$-0.03B |
$0.07B |
-64.08% |
| 2017-12-31 |
$-0.03B |
$0.04B |
-65.61% |
| 2017-09-30 |
$-0.03B |
$0.05B |
-63.27% |
| 2017-06-30 |
$-0.03B |
$0.05B |
-65.67% |
| 2017-03-31 |
$-0.04B |
$0.05B |
-67.61% |
| 2016-12-31 |
$-0.04B |
$0.05B |
-60.76% |
| 2016-09-30 |
$-0.04B |
$0.05B |
-55.22% |
| 2016-06-30 |
$-0.03B |
$0.06B |
-48.23% |
| 2016-03-31 |
$-0.03B |
$0.08B |
-41.10% |
| 2015-12-31 |
$-0.03B |
$0.08B |
-39.37% |
| 2015-09-30 |
$-0.02B |
$0.06B |
-30.49% |
| 2015-06-30 |
$-0.01B |
$0.07B |
-18.69% |
| 2015-03-31 |
$0.00B |
$0.04B |
-8.45% |
| 2014-12-31 |
$0.00B |
$0.05B |
3.92% |
| 2014-09-30 |
$0.00B |
$0.06B |
7.27% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
